Imperial College London

DrKoraliaPaschalaki

Faculty of MedicineNational Heart & Lung Institute

Senior Clinical Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 2728k.paschalaki Website

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Reed:2015:10.1096/fj.14-268144,
author = {Reed, DM and Paschalaki, KE and Starke, RD and Mohamed, NA and Sharp, G and Fox, B and Eastwood, D and Bristow, A and Ball, C and Vessillier, S and Hansel, TT and Thorpe, SJ and Randi, AM and Stebbings, R and Mitchell, JA},
doi = {10.1096/fj.14-268144},
journal = {The FASEB Journal},
pages = {2595--2602},
title = {An autologous endothelial cell: peripheral blood mononuclear cell assay that detects cytokine storm responses to biologics},
url = {http://dx.doi.org/10.1096/fj.14-268144},
volume = {29},
year = {2015}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - There is an urgent unmet need for human tissue bioassays to predict cytokine storm responses to biologics. Current bioassays that detect cytokine storm responses in vitro rely on endothelial cells, usually from umbilical veins or cell lines, cocultured with freshly isolated peripheral blood mononuclear cells (PBMCs) from healthy adult volunteers. These assays therefore comprise cells from 2 separate donors and carry the disadvantage of mismatched tissues and lack the advantage of personalized medicine. Current assays also do not fully delineate mild (such as Campath) and severe (such as TGN1412) cytokine storminducing drugs. Here, we report a novel bioassay where endothelial cells grown from stem cells in the peripheral blood (blood outgrowth endothelial cells) and PBMCs from the same donor can be used to create an autologous coculture bioassay that responds by releasing a plethora of cytokines to authentic TGN1412 but only modestly to Campath and not to control antibodies such as Herceptin, Avastin, and Arzerra. This assay performed better than the traditional mixed donor assay in terms of cytokine release to TGN1412 and, thus, we suggest provides significant advancement and a definitive system by which biologics can be tested and paves the way for personalized medicine.—Reed, D. M., Paschalaki, K. E., Starke, R. D., Mohamed, N. A., Sharp, G., Fox, B., Eastwood, D., Bristow, A., Ball, C., Vessillier, S., Hansel, T. T., Thorpe, S. J., Randi, A. M., Stebbings, R., Mitchell, J. A. An autologous endothelial cell:peripheral blood mononuclear cell assay that detects cytokine storm responses to biologics. FASEB J. 29, 25952602 (2015). www.fasebj.org
AU - Reed,DM
AU - Paschalaki,KE
AU - Starke,RD
AU - Mohamed,NA
AU - Sharp,G
AU - Fox,B
AU - Eastwood,D
AU - Bristow,A
AU - Ball,C
AU - Vessillier,S
AU - Hansel,TT
AU - Thorpe,SJ
AU - Randi,AM
AU - Stebbings,R
AU - Mitchell,JA
DO - 10.1096/fj.14-268144
EP - 2602
PY - 2015///
SN - 0892-6638
SP - 2595
TI - An autologous endothelial cell: peripheral blood mononuclear cell assay that detects cytokine storm responses to biologics
T2 - The FASEB Journal
UR - http://dx.doi.org/10.1096/fj.14-268144
UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000355209500035&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR - https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.14-268144
VL - 29
ER -